More than halfway through the biopharma year, there is no question that 2023 has proven very difficult for many early stage biotech companies, due to heavy ‘right sizing,’ job losses and even company closures.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?